466 related articles for article (PubMed ID: 27862340)
1. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.
Lin M; Mittal S; Sahebjam F; Rana A; Sood GK
Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340
[TBL] [Abstract][Full Text] [Related]
2. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
Nogueras López F; Abellan Alfocea P; Ortega Suazo EJ; López Garrido MA; Becerra Massare A; Gila Medina AM; Redondo Cerezo E; Espinosa Aguilar MD
Transplant Proc; 2020 Mar; 52(2):556-558. PubMed ID: 32035673
[TBL] [Abstract][Full Text] [Related]
3. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.
Su L; Tam N; Deng R; Chen P; Li H; Wu L
Int Urol Nephrol; 2014 Oct; 46(10):2035-44. PubMed ID: 25027805
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study.
Sterneck M; Kaiser GM; Heyne N; Richter N; Rauchfuss F; Pascher A; Schemmer P; Fischer L; Klein CG; Nadalin S; Lehner F; Settmacher U; Gotthardt D; Loss M; Ladenburger S; Wimmer P; Dworak M; Schlitt HJ
Clin Transplant; 2016 Jun; 30(6):741-8. PubMed ID: 27160359
[TBL] [Abstract][Full Text] [Related]
5. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
6. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
Berger SP; Sommerer C; Witzke O; Tedesco H; Chadban S; Mulgaonkar S; Qazi Y; de Fijter JW; Oppenheimer F; Cruzado JM; Watarai Y; Massari P; Legendre C; Citterio F; Henry M; Srinivas TR; Vincenti F; Gutierrez MPH; Marti AM; Bernhardt P; Pascual J;
Am J Transplant; 2019 Nov; 19(11):3018-3034. PubMed ID: 31152476
[TBL] [Abstract][Full Text] [Related]
7. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.
Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
Am J Transplant; 2016 Apr; 16(4):1238-47. PubMed ID: 26820618
[TBL] [Abstract][Full Text] [Related]
8. Everolimus in de novo liver transplant recipients: a systematic review.
Tang CY; Shen A; Wei XF; Li QD; Liu R; Deng HJ; Wu YZ; Wu ZJ
Hepatobiliary Pancreat Dis Int; 2015 Oct; 14(5):461-9. PubMed ID: 26459721
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
10. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of everolimus treatment on liver transplant recipients: A meta-analysis.
Guan TW; Lin YJ; Ou MY; Chen KB
Eur J Clin Invest; 2019 Dec; 49(12):e13179. PubMed ID: 31610022
[TBL] [Abstract][Full Text] [Related]
12. Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients.
Manzia TM; Angelico R; Toti L; Grimaldi C; Sforza D; Vella I; Tariciotti L; Lenci I; Breshanaj G; Baiocchi L; Tisone G
Transplant Proc; 2018; 50(1):175-183. PubMed ID: 29407305
[TBL] [Abstract][Full Text] [Related]
13. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
[TBL] [Abstract][Full Text] [Related]
14. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
[TBL] [Abstract][Full Text] [Related]
15. Randomized Sirolimus-based Early Calcineurin Inhibitor Reduction in Liver Transplantation: Impact on Renal Function.
Buchholz BM; Ferguson JW; Schnitzbauer AA; Nightingale P; Schlitt HJ; Geissler EK; Mirza DF;
Transplantation; 2020 May; 104(5):1003-1018. PubMed ID: 31577671
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of everolimus plus low-dose calcineurin inhibitor vs. mycophenolate mofetil plus standard-dose calcineurin inhibitor in renal transplant recipients: A systematic review and meta-analysis
.
He L; Deng J; Yang B; Jiang W
Clin Nephrol; 2018 May; 89(5):336-344. PubMed ID: 29292693
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppression Modification by Everolimus With Minimization of Calcineurin Inhibitors Recovers Kidney Graft Function Even in Patients With Very Late Conversion and Also With Poor Graft Function.
Nojima M; Yamada Y; Higuchi Y; Shimatani K; Kanematsu A; Yamamoto S
Transplant Proc; 2017; 49(1):41-44. PubMed ID: 28104155
[TBL] [Abstract][Full Text] [Related]
18. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis.
Mocchegiani F; Montalti R; Nicolini D; Svegliati Baroni G; Benedetti A; Risaliti A; Vivarelli M
Ann Transplant; 2014 Oct; 19():545-50. PubMed ID: 25347718
[TBL] [Abstract][Full Text] [Related]
20. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
